Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

被引：4
|
作者：
Chen, Ning [2 ,3 ]
Xu, Xiaoling [1 ]
Fan, Yun [1 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷
基金：
中国国家自然科学基金;
关键词：
biomarker; immune checkpoint inhibitor; immunotherapy; oesophageal squamous cell carcinoma; PD-L1; OPEN-LABEL; TUMOR MICROENVIRONMENT; POOR-PROGNOSIS; PHASE-II; CANCER; NIVOLUMAB; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAMRELIZUMAB; EXPRESSION;
D O I：
10.1177/17588359231189420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
引用
收藏
页数：18
相关论文
共 50 条
  • [1] Lymph node metastasis in oral squamous cell carcinoma: Where we are and where we are going
    Cao, Lei-Ming
    Zhong, Nian-Nian
    Li, Zi-Zhan
    Huo, Fang-Yi
    Xiao, Yao
    Liu, Bing
    Bu, Lin-Lin
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2023, 3 (04):
  • [2] Checkpoint Inhibitors: Where Have We Been and Where Are We Going in Advanced NSCLC?
    Tripathy, Debu
    Horn, Leora
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (07) : 29 - 37
  • [3] The immune checkpoint inhibitors: where are we now?
    Rachel M. Webster
    Nature Reviews Drug Discovery, 2014, 13 : 883 - 884
  • [4] The immune checkpoint inhibitors: where are we now?
    Webster, Rachel
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (12) : 883 - 884
  • [5] First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
    Adashek, Jacob J.
    Breunig, Joshua J.
    Posadas, Edwin
    Bhowmick, Neil A.
    Ellis, Leigh
    Freedland, Stephen J.
    Kim, Hyung
    Figlin, Robert
    Gong, Jun
    DRUGS, 2022, 82 (04) : 439 - 453
  • [6] First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
    Jacob J. Adashek
    Joshua J. Breunig
    Edwin Posadas
    Neil A. Bhowmick
    Leigh Ellis
    Stephen J. Freedland
    Hyung Kim
    Robert Figlin
    Jun Gong
    Drugs, 2022, 82 : 439 - 453
  • [7] Squamous Cell Lung Cancer: Where Do We Stand and Where Are We Going?
    Hirsch, Fred R.
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 914 - 915
  • [8] Treatment planning: where are we and, where are we going
    Bohoudi, O.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S340 - S340
  • [9] Treatment of IBD: Where We Are and Where We Are Going
    Bernstein, Charles N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (01): : 114 - 126
  • [10] Osteoporosis Treatment: Where Are We and Where Are We Going?
    McClung, Michael
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (06): : 1199 - 1199
12345